Pityriasis Lichenoides
Conditions
Brief summary
Primary outcome: The primary outcome at end of study (EOS) is to compare the therapeutic efficacy of Azithromycin in the treatment of pityriasis lichenoides chronica (PLC) with that of a well-documented line of therapy namely narrow band ultra violet B (nbUVB). Secondary outcomes: 1\. To identify the possibility of streptococcal throat infection as a possible underlying etiology in PLC.
Interventions
DRUGAzithromycin
Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
OTHERnbUVB
The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with classic papular eruption of PLC (scaly erythematous papules with mica-like scales) with diagnosis documented histopathologically with or without associated hypopigmented lesions 2. Age: \> 6 years 3. Both sexes.
Exclusion criteria
1. Patients presenting with only hypopigmented macules whom their skin biopsy revealed PLC. 2. Patients with hypopigmented lesions that reveal mycosis fungoides pathologically. 3. Patients with PLC associated with classic MF. 4. Patients with known absolute contraindications to NB-UVB. 5. Patients with impaired liver and/or kidney functions. 6. Patients with history of any heart disease. 7. Patients with known hypersensitivity to Azithromycin \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Azithromycin in treating pityriasis lichenoides chronica | 12 months | The clinical improvement of patients with PLC will be evaluated after taking 3 to 6 cycles of azithromycin and will be compared to the clinical outcome of patients that had three sessions of nbUVB for six to eight weeks. Side effects will be documented in each group |
Countries
Egypt
Contacts
Primary ContactAmira Elbendary, MBBCh, MSc
Backup ContactElbendary, MBBCh, MSc
Outcome results
None listed